Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team
Extensive research

Revenio: Not a one-trick pony

Revenio Group
Download report (PDF)

Revenio is known as the global beacon of tonometers but these days the company is a noteworthy challenger in more extensive ophthalmic health technology. Imaging tools (previous CenterVue) play an increasing role in future growth and HOME products, as well as software business offer longer term growth promises. Business is growing very profitably, the market has sound growth drivers, and the products have strong competitive advantages. In addition, the company has an excellent track record of its ability to create value with investments in product development, structural reorganization, and new long-term growth templates

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures2021-06-08

202021e22e
Revenue61.179.3102.5
growth-%23.4 %29.9 %29.2 %
EBIT (adj.)19.227.237.1
EBIT-% (adj.)31.4 %34.3 %36.2 %
EPS (adj.)0.580.821.10
Dividend0.320.400.55
Dividend %0.6 %2.1 %2.9 %
P/E (adj.)86.623.117.4
EV/EBITDA61.517.812.6

Forum discussions

Well, now it’s high time to jump ship. Getinge, Volati, and Revenio all seem to have gotten undeserved appreciation during the corona turmoil...
3/31/2026, 12:44 PM
by tankerous
10
Bråsen’s predictions were pretty accurate when he worked as an analyst for DI. Four other companies might also be worth looking into. Swedes...
3/31/2026, 12:39 PM
by Matkalle...
8
In Revenio, Bråse sees a severely depressed valuation accelerating growth The picks from this fund manager with “clear” upside potential are...
3/31/2026, 11:57 AM
by Opa
8
Spotted on Nordnet, nothing new or amazing, but perhaps people will wake up a bit regarding Revenio:
3/31/2026, 10:29 AM
by MTES
21
This is a pretty convincing picture. Halfway to becoming a Dividend Aristocrat. Are the years when the dividend remained the same counted, or...
3/23/2026, 3:16 PM
by Sissos
13
However, this point is interesting: 20. Amendment of Article 4 of the Articles of Association The Board of Directors proposes that Article 4...
3/23/2026, 2:55 PM
by Sissos
35
Revenio Group Revenio Group Oyj: Yhtiökokouskutsu 2026 The notice of the Annual General Meeting (AGM) has now been issued. The AGM will be held...
3/23/2026, 2:50 PM
by Temew
8
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.